TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34238552

Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34238577

Group type: EXPERIMENTAL
Intervention: Visual Illusions (VI) in Parkinson's Disease (PD-I)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Visual Hallucinations (VH) in Parkinson's Disease (PD-H)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both groups (PD-I and PD-H)
Number of subjects: 54
Study: 34238753

Group type: EXPERIMENTAL
Intervention: Interdisciplinary home visits over 1 year
Number of subjects: 65
Study: 34238782

Group type: EXPERIMENTAL
Intervention: Higher PEEP (n=259)
Number of subjects: 933

Group type: COMPARATOR
Intervention: Lower PEEP (n=674)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Higher PEEP (matched cohort)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Higher PEEP (unmatched and matched cohorts)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Higher PEEP
Number of subjects: 933
Study: 34238979

Group type: EXPERIMENTAL
Intervention: Tamarkoz (Sufi meditation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Campus health center's stress management resources
Number of subjects: 0
Study: 34239585

Group type: EXPERIMENTAL
Intervention: Qigong practice (ongoing practitioners)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Qigong practice (new practitioners)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Qigong practice
Number of subjects: 43
Study: 34239811

Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 22
Study: 34240242

Group type: EXPERIMENTAL
Intervention: PUG
Number of subjects: 25
Study: 34240339

Group type: EXPERIMENTAL
Intervention: Dasatinib (60 or 80 mg/m2)
Number of subjects: 20
Study: 34241652

Group type: EXPERIMENTAL
Intervention: Increased uptake intervention
Number of subjects: 129
Study: 34241781

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 21 days until progressive disease, unacceptable adverse event, or completion of 24 months of treatment.
Number of subjects: 20
Study: 34241812

Group type: EXPERIMENTAL
Intervention: Post-lockdown HbA1c levels
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Weight changes
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Healthcare access
Number of subjects: 870
Study: 34242221

Group type: EXPERIMENTAL
Intervention: Intermuscular adipose tissue (IMAT) index
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT) index
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: IMAT index after adjustment for BMI and waist circumference
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: SAT index after adjustment for BMI and waist circumference
Number of subjects: 1744
Study: 34242387

Group type: EXPERIMENTAL
Intervention: rFIXFc
Number of subjects: 33
Study: 34242388

Group type: EXPERIMENTAL
Intervention: Panobinostat (PANO) 5 mg orally 3 times a week for 26 weeks, starting on day -5, in combination with tacrolimus and sirolimus.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Panobinostat (PANO)
Number of subjects: 38
Study: 34242478

Group type: EXPERIMENTAL
Intervention: Post-ESWL pancreatitis
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Post-ERCP pancreatitis (PEP)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Independent protective factors for post-ESWL pancreatitis
Number of subjects: 714

Group type: COMPARATOR
Intervention: Risk factors for PEP
Number of subjects: 714
Study: 34242857

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MW)
Number of subjects: 23
Study: 34243720

Group type: EXPERIMENTAL
Intervention: Preoperative interscalene nerve block
Number of subjects: 29

Group type: COMPARATOR
Intervention: Postoperative interscalene nerve block
Number of subjects: 29

Group type: COMPARATOR
Intervention: Patients with intermediate-high risk or confirmed obstructive sleep apnea
Number of subjects: 29
Study: 34243799

Group type: EXPERIMENTAL
Intervention: Protamine administration
Number of subjects: 100
Study: 34243885

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training sessions (15 sessions)
Number of subjects: 15
Study: 34244116

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus axitinib
Number of subjects: 429

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 429
Study: 34244298

Group type: EXPERIMENTAL
Intervention: Multiplexed engineering approach using lentiviruses for CAR T-cell immunotherapy
Number of subjects: 0
Study: 34244325

Group type: EXPERIMENTAL
Intervention: Oral and intravenous doses of phosphorus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 0
Study: 34244538

Group type: EXPERIMENTAL
Intervention: Serum urate (SU) concentrations measured once in blood collected 1997-2000.
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Serum urate (SU) as a continuous variable in women.
Number of subjects: 973
Study: 34244670

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 507
Study: 34244969

Group type: EXPERIMENTAL
Intervention: rSS=0
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 0<rSS≤8
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: rSS>8
Number of subjects: 274
Study: 34244970

Group type: EXPERIMENTAL
Intervention: FACIT-F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-36 Vitality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LupusQoL Fatigue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled fatigue items
Number of subjects: 0
Study: 34245272

Group type: EXPERIMENTAL
Intervention: Colistin resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine reduced susceptibility
Number of subjects: 0
Study: 34245496

Group type: EXPERIMENTAL
Intervention: Gilteritinib plus allogenic peripheral blood stem cell transplantation
Number of subjects: 1
Study: 34245635

Group type: EXPERIMENTAL
Intervention: HINTS test
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: STANDING test
Number of subjects: 300

Group type: COMPARATOR
Intervention: ABCD2 score
Number of subjects: 300
Study: 34245684

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 730
Study: 34245802

Group type: EXPERIMENTAL
Intervention: Hyper-palatable carbohydrate and sodium (CSOD) foods
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hyper-palatable fat and sodium (FSOD) foods
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: High energy dense (HED) foods
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ultra-processed foods (UPF)
Number of subjects: 82
Study: 34246305

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline expression of RA skeletal muscle genes
Number of subjects: 0
Study: 34246328

Group type: EXPERIMENTAL
Intervention: Nomograms developed from predictors including time since initial diagnosis, chemotherapy status, baseline haemoglobin concentration.
Number of subjects: 270
Study: 34246460

Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV) during Preload Responsiveness (PLR)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV) during Tidal Volume Challenge (TVC)
Number of subjects: 54
Study: 34246461

Group type: EXPERIMENTAL
Intervention: Remimazolam 0.1 mg/kg (single bolus) in hepatic impairment trial
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Remimazolam in renal impairment trial
Number of subjects: 43
Study: 34246725

Group type: EXPERIMENTAL
Intervention: Polyvascular disease (PVD)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Polyvascular disease (PVD) among patients with VIS <84
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Non-polyvascular disease (non-PVD) among patients with VIS <84
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Polyvascular disease (PVD) among patients with VIS ≥84
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Non-polyvascular disease (non-PVD) among patients with VIS ≥84
Number of subjects: 1247
Study: 34247126

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) treatment
Number of subjects: 983
Study: 34247273

Group type: EXPERIMENTAL
Intervention: CC-90002
Number of subjects: 0
Study: 34247489

Group type: EXPERIMENTAL
Intervention: Elevated miRNAs in PPCM plasma targeting ERBB4
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: miR-146a, miR-199a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, miR-130a-5p, and miR-135-3p overexpression
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (postpartum-matched healthy CTRLs)
Number of subjects: 33
Study: 34248712

Group type: EXPERIMENTAL
Intervention: Smartwatch monitoring for cocaine use detection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methods of cocaine use detection
Number of subjects: 0
Study: 34248840

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic clamp with induced normoglycemia (4.5 ± 0.07 mmol/L for 1 hour) in T2D
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Proteomic analysis for complement and coagulation cascades using SOMA-scan
Number of subjects: 46
Study: 34248841

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (induced by hyperinsulinemic clamp over 1-hour)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (aged-matched, n = 23)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEi) therapies in T2D subjects
Number of subjects: 23
Study: 34249349

Group type: EXPERIMENTAL
Intervention: Xenografts established from surgical specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34249690

Group type: EXPERIMENTAL
Intervention: Plasma protein profile assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA (ctDNA) quantification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood cell counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumour RNA signature analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TILs quantity assessment
Number of subjects: 0
Study: 34249763

Group type: EXPERIMENTAL
Intervention: Intravitreal methotrexate (MTX, 400 μg, 0.1 mL) injections for 1 year (total 16 injections) and six cycles of rituximab (375 mg/m2).
Number of subjects: 0
Study: 34250257

Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 220
Study: 34250266

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34250397

Group type: EXPERIMENTAL
Intervention: Large gene panel cfDNA NGS
Number of subjects: 25
Study: 34250492

Group type: EXPERIMENTAL
Intervention: 0.55-T MRI system
Number of subjects: 24

Group type: COMPARATOR
Intervention: CT scans
Number of subjects: 24
Study: 34250546

Group type: EXPERIMENTAL
Intervention: Positive perception of birth pain
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Positive provider communication
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pain scores recorded during labor
Number of subjects: 112
Study: 34250553

Group type: EXPERIMENTAL
Intervention: Seribantumab 40/20 mg/kg (loading dose followed by maintenance dose)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Seribantumab (various doses: 3.2, 6, 10, 15, or 20 mg/kg weekly)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Seribantumab
Number of subjects: 44
Study: 34250583

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 736

Group type: COMPARATOR
Intervention: Switched to CT-P13
Number of subjects: 736
Study: 34250820

Group type: EXPERIMENTAL
Intervention: Intracranial blood
Number of subjects: 28
Study: 34251287

Group type: EXPERIMENTAL
Intervention: NE3107
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 34251338

Group type: EXPERIMENTAL
Intervention: Increased theta/alpha synchrony in the habenula-prefrontal network during negative emotional stimuli
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Correlation of theta/alpha band synchronization
Number of subjects: 9
Study: 34251454

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 25187
Study: 34251495

Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CCL3
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 192

Group type: COMPARATOR
Intervention: Febrile controls without UTI
Number of subjects: 192

Group type: COMPARATOR
Intervention: Asymptomatic healthy controls
Number of subjects: 192
Study: 34251540

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measurement
Number of subjects: 201
Study: 34251587

Group type: EXPERIMENTAL
Intervention: UEScope with hockey stick-shaped malleable stylet
Number of subjects: 808
Study: 34251649

Group type: EXPERIMENTAL
Intervention: Aprocitentan (up to 600 mg single dose and 100 mg once daily at multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprocitentan
Number of subjects: 0
Study: 34251685

Group type: EXPERIMENTAL
Intervention: Timing of surgery following SARS-CoV-2 infection
Number of subjects: 0
Study: 34252000

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity level (PAL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Physician-assessed physical activity level (PAL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Respiratory symptoms throughout the day
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Active patients (PAL ≥150 minutes/week)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Interrelation of PALs and symptoms
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GOLD classification groups
Number of subjects: 102
Study: 34252066

Group type: EXPERIMENTAL
Intervention: Low DARS (<28.755)
Number of subjects: 139
Study: 34252125

Group type: EXPERIMENTAL
Intervention: Transfusions
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Extracorporeal life support (ECLS)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Changes in aspartate aminotransferase (ASAT)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Sequential organ failure assessment (SOFA) score
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: SOFA platelet count
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 268
Study: 34252292

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM) use
Number of subjects: 0
Study: 34252375

Group type: EXPERIMENTAL
Intervention: HER2-low-positive tumours
Number of subjects: 2310

Group type: COMPARATOR
Intervention: HER2-zero tumours
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: HER2-low-positive tumours (hormone receptor-negative)
Number of subjects: 2310

Group type: COMPARATOR
Intervention: HER2-zero tumours (hormone receptor-negative)
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: HER2-low-positive tumours (hormone receptor-positive)
Number of subjects: 2310

Group type: COMPARATOR
Intervention: HER2-zero tumours (hormone receptor-positive)
Number of subjects: 2310
Study: 34252397

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34252876

Group type: EXPERIMENTAL
Intervention: Florbetapir and PiB cerebellar SUVR_pons in carriers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebellar SUVR_pons
Number of subjects: 0
Study: 34252909

Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 256
Study: 34253172

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day until disease progression or other withdrawal criteria
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 88
Study: 34253175

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measures of cerebral saturation (Csat)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measures of renal saturation (Rsat)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Renal and cerebral fractional tissue oxygen extraction (rFTOE and cFTOE)
Number of subjects: 49
Study: 34253255

Group type: EXPERIMENTAL
Intervention: Postoperative NT-proBNP measurement on POD1
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Postoperative NT-proBNP measurement on POD3
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Postoperative NT-proBNP measurement on POD1 in severe PHF
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Postoperative NT-proBNP measurement on POD3 in severe PHF
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Postoperative change of NT-proBNP
Number of subjects: 382
Study: 34253376

Group type: EXPERIMENTAL
Intervention: Locoregional melphalan chemotherapy (hyperthermic isolated limb perfusion)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Locoregional melphalan chemotherapy (isolated limb infusion)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hypoxic pelvic and limb perfusion
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Locoregional melphalan chemotherapy
Number of subjects: 62
Study: 34253565

Group type: EXPERIMENTAL
Intervention: Low-inflammatory diet based on the Mediterranean diet
Number of subjects: 28
Study: 34253577

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily until disease progression or unacceptable toxicity
Number of subjects: 44
Study: 34253579

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NAT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Higher TCR clonality
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PD-L1 positivity
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Higher CD3+:CD68+ ratio
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Closer spatial proximity of T cells to tumor cells
Number of subjects: 105
Study: 34253587

Group type: EXPERIMENTAL
Intervention: Donor-specific HLA antibody (DSA) positivity in NR biopsies
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Machine learning DSA probability
Number of subjects: 835

Group type: COMPARATOR
Intervention: Biopsies classified as no rejection (NR)
Number of subjects: 835
Study: 34253595

Group type: EXPERIMENTAL
Intervention: ABBV-744
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABBV-744 + Venetoclax
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABBV-075
Number of subjects: 0
Study: 34253597

Group type: EXPERIMENTAL
Intervention: KPT-9274-everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: everolimus
Number of subjects: 0
Study: 34253733

Group type: EXPERIMENTAL
Intervention: AAV2-hAADC delivered via convection-enhanced delivery (CED) to the bilateral substantia nigra (SN) and ventral tegmental area (VTA) with a total infusion volume of 80 µL per hemisphere.
Number of subjects: 7
Study: 34253928

Group type: EXPERIMENTAL
Intervention: HER2-specific CAR T cells via locoregional infusion
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study: 34254126

Group type: EXPERIMENTAL
Intervention: Siemens Atellica IM hs-cTnI assay
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Guideline-recommended application of an established hs-cTnI assay
Number of subjects: 1800
Study: 34255063

Group type: EXPERIMENTAL
Intervention: Iodine-containing supplement initiated prepregnancy and continued through pregnancy
Number of subjects: 137

Group type: COMPARATOR
Intervention: No use of supplement
Number of subjects: 137
Study: 34255078

Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 0.5 g·min-1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 1.0 g·min-1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 1.5 g·min-1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 2 g·min-1
Number of subjects: 13
Study: 34255140

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment initiated or increased
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Treatment increased
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Initial PGA score
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy increased
Number of subjects: 1006
Study: 34255353

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²
Number of subjects: 118
Study: 34255535

Group type: EXPERIMENTAL
Intervention: BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ≤ 2 years
Number of subjects: 41
Study: 34255555

Group type: EXPERIMENTAL
Intervention: Food Supplement with Antioxidative Santa Herba Extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34255642

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program (n=70, 56 completed the program)
Number of subjects: 140
Study: 34255658

Group type: EXPERIMENTAL
Intervention: Web-based intervention with human support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple recruitment and retention strategies
Number of subjects: 0
Study: 34255722

Group type: EXPERIMENTAL
Intervention: HIPPER intervention consisting of 12 online, interactive modules
Number of subjects: 40

Group type: COMPARATOR
Intervention: Current standard practice consisting of 2 online educational sessions lasting 2 hours each (webinars)
Number of subjects: 40
Study: 34255727

Group type: EXPERIMENTAL
Intervention: VoiceAdapt mobile therapy app, used for 5 weeks of training.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control group, no training for 5 weeks followed by 5 weeks of training with VoiceAdapt.
Number of subjects: 80
Study: 34255901

Group type: EXPERIMENTAL
Intervention: Autologous invariant natural killer T (iNKT) cells
Number of subjects: 10
Study: 34255974

Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Number of subjects: 0
Study: 34256007

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34256279

Group type: EXPERIMENTAL
Intervention: Alisertib 40 mg BID on D1-3 per week plus nab-paclitaxel 100 mg/m²
Number of subjects: 31
Study: 34256305

Group type: EXPERIMENTAL
Intervention: Weekly AAT augmentation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silencing AAT production, improving protein folding and secretion, promoting AAT degradation
Number of subjects: 0